SEC Form 10-K filed by Actuate Therapeutics Inc.
$ACTU
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $21.00 | Buy | Craig Hallum |
| 3/17/2025 | $20.00 | Buy | H.C. Wainwright |
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)
Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCOIn-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will host an in-person key opinion leader (KOL) event, during the 2025 American
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control armElraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysisClinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rateElraglusib/GnP combination arm demonstrated a favorable risk-benefit profileTopline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting Company plans to work with regulators to expeditiously bring elraglusib to commercialization CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actua
CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at the Citizens Life Sciences Conference 2025 taking place May 7-8 in New York, NY. Citizens JMP Life Sciences Conference Presentation Date:Thursday, May 8, 2025Time:12:30 PM ETWebcast Link:click here The webcast of the presentation will be accessib
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
EFFECT - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
424B3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00
H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00